Another well-studied function of DOT1L is its pro-tumorigenic effect, especially in the MLL-rearranged leukemia, and targeting DOT1L has therefore been proposed as a potential therapeutic approach (McLean et al., 2014; Boehm and Ott, 2017; Sarno et al., 2020). The gene discussed is KMT2A; the disease is leukemia.